Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Analyst Ratings
Moderate Buy
10 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
APLS Stock 12 Month Forecast
Average Price Target
$36.06
▲(57.12%Upside)
| Highest Price Target$60.00 | Average Price Target$36.06 | Lowest Price Target$19.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$24
Hold
4.58%
Upside
Reiterated
08/02/25
Apellis Pharmaceuticals' overall score is driven by strong technical momentum and promising developments in its product pipeline, particularly EMPAVELI. However, profitability challenges and valuation concerns weigh on the score. The company's strategic initiatives, including the royalty buy-down deal, provide a positive outlook for financial stability and future growth.
H.C. Wainwright
$83→$57
Buy
148.37%
Upside
Reiterated
08/01/25
Raymond James
$52→$50
Buy
117.86%
Upside
Reiterated
08/01/25
Cantor Fitzgerald
$39.2→$40
Buy
74.29%
Upside
Reiterated
07/31/25
Goldman Sachs
$24→$26
Hold
13.29%
Upside
Reiterated
07/31/25
TD Cowen
$50
Buy
117.86%
Upside
Reiterated
07/31/25
Bank of America Securities
$25→$26
Hold
13.29%
Upside
Reiterated
07/31/25
RBC Capital
$17→$19
Hold
-17.21%
Downside
Reiterated
07/31/25
Morgan Stanley
$26
Hold
13.29%
Upside
Reiterated
07/31/25
Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli ExpansionWe will remain interested in indications of overall GA market growth, but can now look toward early signs of launch contribution from an expanded Empaveli label as well as we head into late 2025.
Scotiabank
$20→$22
Hold
-4.14%
Downside
Reiterated
07/30/25
Needham
$29
Buy
26.36%
Upside
Reiterated
07/29/25
Citi
$41→$46
Buy
100.44%
Upside
Reiterated
07/29/25
Stifel Nicolaus
$60
Buy
161.44%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
Mizuho Securities
$20→$21
Hold
-8.50%
Downside
Reiterated
07/29/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$24
Hold
4.58%
Upside
Reiterated
08/02/25
Apellis Pharmaceuticals' overall score is driven by strong technical momentum and promising developments in its product pipeline, particularly EMPAVELI. However, profitability challenges and valuation concerns weigh on the score. The company's strategic initiatives, including the royalty buy-down deal, provide a positive outlook for financial stability and future growth.
H.C. Wainwright
$83→$57
Buy
148.37%
Upside
Reiterated
08/01/25
Raymond James
$52→$50
Buy
117.86%
Upside
Reiterated
08/01/25
Cantor Fitzgerald
$39.2→$40
Buy
74.29%
Upside
Reiterated
07/31/25
Goldman Sachs
$24→$26
Hold
13.29%
Upside
Reiterated
07/31/25
TD Cowen
$50
Buy
117.86%
Upside
Reiterated
07/31/25
Bank of America Securities
$25→$26
Hold
13.29%
Upside
Reiterated
07/31/25
RBC Capital
$17→$19
Hold
-17.21%
Downside
Reiterated
07/31/25
Morgan Stanley
$26
Hold
13.29%
Upside
Reiterated
07/31/25
Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli ExpansionWe will remain interested in indications of overall GA market growth, but can now look toward early signs of launch contribution from an expanded Empaveli label as well as we head into late 2025.
Scotiabank
$20→$22
Hold
-4.14%
Downside
Reiterated
07/30/25
Needham
$29
Buy
26.36%
Upside
Reiterated
07/29/25
Citi
$41→$46
Buy
100.44%
Upside
Reiterated
07/29/25
Stifel Nicolaus
$60
Buy
161.44%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
Mizuho Securities
$20→$21
Hold
-8.50%
Downside
Reiterated
07/29/25
Best Analysts Covering Apellis Pharmaceuticals
1 Month
xxx
Success Rate
19/29 ratings generated profit
Average Return
+4.96%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.52% of your transactions generating a profit, with an average return of +4.96% per trade.
3 Months
xxx
Success Rate
18/28 ratings generated profit
Average Return
+4.82%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +4.82% per trade.
1 Year
Success Rate
14/30 ratings generated profit
Average Return
+3.99%
reiterated a buy rating 6 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +3.99% per trade.
2 Years
xxx
Success Rate
15/28 ratings generated profit
Average Return
+1.47%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.57% of your transactions generating a profit, with an average return of +1.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
APLS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
18
17
11
18
12
Buy
5
6
5
7
5
Hold
22
23
21
33
25
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
46
37
58
42
Each month's total comprises the sum of three months' worth of ratings.
APLS Financial Forecast
APLS Stock Forecast FAQ
What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 36.06.
What is APLS’s upside potential, based on the analysts’ average price target?
Apellis Pharmaceuticals Inc has 57.12% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is APLS a Buy, Sell or Hold?
Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 10 buy ratings, 8 hold ratings and 0 sell ratings.
What is Apellis Pharmaceuticals Inc’s price target?
The average price target for Apellis Pharmaceuticals Inc is 36.06. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $19.00. The average price target represents 57.12% Increase from the current price of $22.95.
The highest analyst price target is $60.00 ,the lowest forecast is $19.00. The average price target represents 57.12% Increase from the current price of $22.95.
What do analysts say about Apellis Pharmaceuticals Inc?
Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of APLS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.